Další formáty:
BibTeX
LaTeX
RIS
@article{967797,
author = {Basak, Grzegorz W. and Jaksic, Ozren and Kořístek, Zdeněk and Mikala, Gabor and Mayer, Jiří and Masszi, Tamas and Labar, Boris and WiktorandJedrzejczak, Wieslaw},
article_number = {7},
doi = {http://dx.doi.org/10.1002/ajh.22038},
keywords = {NON-HODGKINS-LYMPHOMA; LENALIDOMIDE THERAPY; MULTIPLE-MYELOMA; PROGENITOR CELLS; BLOOD; TRANSPLANTATION; PREDICTION; EXPERIENCE; COLLECTION; INHIBITOR},
language = {eng},
issn = {0361-8609},
journal = {American Journal of Hematology},
title = {Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization},
volume = {86},
year = {2011}
}
TY - JOUR
ID - 967797
AU - Basak, Grzegorz W. - Jaksic, Ozren - Kořístek, Zdeněk - Mikala, Gabor - Mayer, Jiří - Masszi, Tamas - Labar, Boris - Wiktor-Jedrzejczak, Wieslaw
PY - 2011
TI - Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization
JF - American Journal of Hematology
VL - 86
IS - 7
SP - 550-553
EP - 550-553
SN - 03618609
KW - NON-HODGKINS-LYMPHOMA
KW - LENALIDOMIDE THERAPY
KW - MULTIPLE-MYELOMA
KW - PROGENITOR CELLS
KW - BLOOD
KW - TRANSPLANTATION
KW - PREDICTION
KW - EXPERIENCE
KW - COLLECTION
KW - INHIBITOR
N2 - The introduction of plerixafor has enabled successful collection of stem cells in the majority of patients with lymphoma or myeloma in whom previous attempts at mobilization have failed. However, a proportion of patients have been shown to be resistant to this mobilization regimen. To identify the factors that impair stem cell mobilization and collection with plerixafor, we reviewed the data for 197 patients who had undergone mobilization with plerixafor and granulocyte-colony stimulating factor in Central Europe. Predictors of mobilization failure were evaluated using logistic regression analysis. Among the 197 patients mobilized, the target of more than 2.0 x 10(6) CD34+ cells/kg was collected from 133 (67.5%). Our analysis revealed that previous treatment with lenalidomide, bortezomib, melphalan, radiotherapy, or autologous stem cell transplantation and regimen of plerixafor use in combination with chemotherapy had no significant effect on the efficiency of collection. In contrast, an age >= 65 years (odds ratio 0.331, 95% CI: 0.112-0.977, P less than 0.05), a diagnosis of non-Hodgkin's lymphoma (odds ratio 0.277, 95% CI: 0.124-0.622, P less than 0.01), and treatment with less than four chemotherapy regimens (odds ratio 0.366, 95% CI: 0.167-0.799, P less than 0.05) were associated significantly with failed mobilization. The rate of successful mobilizations was decreased in patients treated with purine analogues (odds ratio 0.323, 95% CI: 0.096-1.094, P = 0.07) but increased in female patients (odds ratio 1.961, CI: 0.943-4.080, P = 0.07). Patients who are characterized by the above negative features could benefit potentially from further improvement in the mobilization strategy.
ER -
BASAK, Grzegorz W., Ozren JAKSIC, Zdeněk KOŘÍSTEK, Gabor MIKALA, Jiří MAYER, Tamas MASSZI, Boris LABAR a Wieslaw WIKTOR-JEDRZEJCZAK. Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization. \textit{American Journal of Hematology}. 2011, roč.~86, č.~7, s.~550-553. ISSN~0361-8609. Dostupné z: https://dx.doi.org/10.1002/ajh.22038.
|
